Life
Briefing: Clearing tumors in mice, Azalea Therapeutics advances dream of in vivo CAR-T therapy
Strategic angle: A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut costs and expand access.
editorial-staff
1 min read
Updated 24 days ago
Azalea Therapeutics recently reported on a mouse study focused on in vivo CAR-T therapy, showcasing the potential for precise gene editing in the engineering of CAR-T cells.
This approach could significantly alter the landscape of CAR-T therapy by potentially reducing costs and improving access for patients.
The implications of this study extend to the operational frameworks of cancer treatment, suggesting a shift towards more efficient therapeutic strategies.